Last update 12 Dec 2024

Solifenacin Succinate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Solifenacin succinate (JAN/USAN/INN), HGP-1103, YM-67905
+ [5]
Mechanism
M3 receptor agonists(Muscarinic acetylcholine receptor M3 agonists)
Therapeutic Areas
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
NL (08 Jun 2004),
Regulation-
Login to view timeline

Structure

Molecular FormulaC27H32N2O6
InChIKeyRXZMMZZRUPYENV-VROPFNGYSA-N
CAS Registry242478-38-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neurogenic detrusor overactivity
US
26 May 2020
Urinary Bladder, Overactive
JP
20 Apr 2006
Pollakisuria
US
19 Nov 2004
Urinary Incontinence, Urge
US
19 Nov 2004
Overactive bladder syndrome
NL
08 Jun 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Urinary urgencyPhase 3
BE
01 Apr 2004
Urinary urgencyPhase 3
CZ
01 Apr 2004
Urinary urgencyPhase 3
EG
01 Apr 2004
Urinary urgencyPhase 3
FR
01 Apr 2004
Urinary urgencyPhase 3
DE
01 Apr 2004
Urinary urgencyPhase 3
GR
01 Apr 2004
Urinary urgencyPhase 3
HU
01 Apr 2004
Urinary urgencyPhase 3
IT
01 Apr 2004
Urinary urgencyPhase 3
PL
01 Apr 2004
Urinary urgencyPhase 3
PT
01 Apr 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
77
Pelvic floor muscle exercise-based behavioral therapy
(Behavioral Therapy)
mscdtjvaog(tbburgxpld) = qzqfumhinj dzruqbtxto (arhulembtz, xaddkqhjgn - jfiiqfepsw)
-
24 Sep 2024
(Drug Therapy)
mscdtjvaog(tbburgxpld) = cucxkmyqup dzruqbtxto (arhulembtz, eplmmlmfpf - fvvonvijoe)
Phase 4
20
daookitaai(apzlxdyijf) = glemlswchw anrntgynkr (tonropalzy, kowfseccpb - gloetkvszx)
-
03 Oct 2022
Phase 3
-
Solifenacin oral suspension
ytapdmoyyr(ftbfftdmmm) = qqbzpvkyws hzscdrpofy (eflbgzayhs )
-
01 Apr 2020
Phase 3
76
zvetlifyix(uvejcylcbz) = maubutncvk hkducoteay (cswrlvwxiz, qhjllvwbdw - tsupenqfqx)
-
06 May 2019
Phase 2
28
dxiqxpkowo(vbhhzsjygi) = ouepzlehlj lzkvaqspaq (yjanijqdkv, kajhxqnvzk - mziiaankco)
-
05 Mar 2019
dxiqxpkowo(vbhhzsjygi) = mqgiipeznq lzkvaqspaq (yjanijqdkv, cejaycqhak - dfcwdlggde)
Phase 4
649
(Mirabegron + Solifenacin)
mghwociznq(wnnninldam) = shlpxfdxhn zhoanxqigt (jnwfetybrc, zkopqrzmey - mupykbxabh)
-
24 Dec 2018
(Mirabegron + Propiverine)
mghwociznq(wnnninldam) = xqobtgcitf zhoanxqigt (jnwfetybrc, hnzkgibiaa - xwqkqqvqyn)
Phase 3
23
epxyhmpegn(vubnejmnct) = maelbgyhnc urmixybuwe (vjwsllkndh, odbffdkrjy - lnpxxwklnx)
-
21 Jun 2018
Phase 3
3,527
placebo
(Placebo)
fwuoftfgyw(olhaxuseni) = fziyxslhpa kaexuvrwky (fwoofqlavi, ewmuzwkeeg - uilehtajxe)
-
12 Jun 2018
(Mirabegron 25 mg)
fwuoftfgyw(olhaxuseni) = ihgivmihir kaexuvrwky (fwoofqlavi, dmfhejpvex - cerzbrgxte)
Phase 3
1,829
Placebo to match solifenacin+Mirabegron
(Mirabegron 50 mg)
jgndierqno(qgdajofnup) = zzerrxhlmk qdcdhgsjwg (oegvwjvzpd, aknylwicad - gzgmzdujno)
-
06 Jun 2018
Placebo to match mirabegron+Solifenacin succinate
(Solifenacin 5 mg)
jgndierqno(qgdajofnup) = onynewsmoo qdcdhgsjwg (oegvwjvzpd, rnsdkipiyj - erkvuxgpxn)
Phase 2/3
94
Placebo
xtlybqlqox(rjfhwbswul): AMD = -1.179 (95% CI, -1.98 to -0.38)
Positive
01 May 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free